Select Publications
Journal articles
2009, 'Quantifying the dose-response of walking in reducing coronary heart disease risk: Meta-analysis', European Journal of Epidemiology, 24, pp. 181 - 192, http://dx.doi.org/10.1007/s10654-009-9328-9
,2009, 'Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial', Clinical Infectious Diseases, 49, pp. 1591 - 1601
,2009, 'The pattern of excess cancer in dialysis and transplantation', Nephrology Dialysis Transplantation, 24, pp. 3225 - 3231, http://dx.doi.org/10.1093/ndt/gfp331
,2009, 'Thrombocytopenia is strongly associated with simian AIDS in pigtail macaques', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 51, pp. 374 - 379
,2008, 'A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand', Hepatology, 48, pp. 1062 - 1069
,2008, 'Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries', Journal of Gastroenterology and Hepatology, 23, pp. 922 - 929, http://dx.doi.org/10.1111/j.1440-1746.2007.05065.x
,2007, 'Causes of death in hepatitis B and C: a methodological issue', Lancet, 370, pp. 1033, http://dx.doi.org/10.1016/S0140-6736(07)61473-1
,2007, 'High Incidence of hepatitis C virus reinfection within a cohort of injecting drug users', Journal of Viral Hepatitis, 14, pp. 413 - 418
,2007, 'Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study', Australian and New Zealand Journal of Public Health, 31, pp. 475 - 482
,2007, 'Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users', Epidemiology and Infection, 135, pp. 144 - 150
,2007, 'Predictors of completion of a hepatitis Bvaccination schedule in attendees at a primary health care centre.', Sexual Health, 4, pp. 27 - 30
,2006, 'Mortality in patients with hepatitis B or hepatitis C - Authors' reply', Lancet, 368, pp. 1767, http://dx.doi.org/10.1016/S0140-6736(06)69729-8
,2006, 'Cancer incidence in people with hepatitis B or C infection: A large community-based linkage study', Journal of Hepatology, 45, pp. 197 - 203
,2006, 'Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study', Lancet, 368, pp. 938 - 945
,2006, 'Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: The ALLIANCE Study', Antiviral Therapy, 11, pp. 409 - 419
,2006, 'Is screening for sexually transmitted infections in men who have sex with men who receive non-occupational HIV post-exposure prophylaxis worthwhile?', Sexually Transmitted Infections, 82, pp. 21 - 23
,2006, 'Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis', Clinical Cancer Research, 12, pp. 89 - 96
,2006, 'Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy', HIV Medicine, 7, pp. 105 - 111
,2006, 'Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individuals', AIDS Research and Human Retroviruses, 22, pp. 338 - 341
,2005, 'Cancer incidence in people with hepatitis B or C infection: A population based cohort study', Journal of Hepatology, 42, pp. 88 - 88, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000229024000228&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
,2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, 56, pp. 380 - 387
,2005, 'Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy', Journal of Gastroenterology and Hepatology, 20, pp. 1082 - 1086
,2005, 'Sexual behaviour and human herpesvirus 8 infection in homosexual men in Australia.', Sexual Health, 2, pp. 13 - 18
,2005, 'The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals', AIDS, 19, pp. 1393 - 1399
,2005, 'The use of a triple nucleoside-nucleotide-regimen for occupational HIV post-exposure prophylaxis', HIV Medicine, 6, pp. 191 - 197
,2004, 'Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: A meta-analysis of six prospective, randomized, comparative studies', Clinical Therapeutics, 26, pp. 92 - 97
,2004, 'Clearance of hepatitis C virus after newly acquired infection ininjection drug users', Journal of Infectious Diseases, 190, pp. 1270 - 1274
,2004, 'Hepatitis C virus incidence among injecting drug users on opioid replacement therapy', Australian and New Zealand Journal of Public Health, 28, pp. 576 - 578
,2004, 'HIV and hepatitis C coinfection within the CAESAR study', HIV Medicine, 5, pp. 174 - 179
,2004, 'Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study', AIDS, 18, pp. 1029 - 1036, http://www.medscape.com/viewarticle/474870
,2003, 'Combined Analysis of Two-Year Follow-Up from Two Open-Label Randomized Trials Comparing Efficacy of Three Nucleoside Reverse Transcriptase Inhibitor Backbones for Previously Untreated HIV-1 Infection: OzCombo 1 and 2', HIV Research & Clinical Practice, 4, pp. 252 - 261, http://dx.doi.org/10.1310/hct.2003.4.4.004
,2003, '229 Hepatitis C virus reinfection within a cohort of injecting drug users', Hepatology, 38, pp. 266 - 266, http://dx.doi.org/10.1016/s0270-9139(03)80272-0
,2003, 'Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2', HIV Clinical Trials, 4, pp. 252 - 261
,2002, 'Insulin resistance and HIV-related lipoatrophy [1] (multiple letters)', Journal of the American Medical Association, 288, pp. 1716, http://dx.doi.org/10.1001/jama.288.14.1716
,2002, 'Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study', HIV Research & Clinical Practice, 3, pp. 177 - 185, http://dx.doi.org/10.1310/hct.2002.3.3.001
,2002, 'A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia', AIDS, 16, pp. 2195 - 2200
,2002, 'Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy', JAMA - Journal of the American Medical Association, 288, pp. 207 - 215
,2002, 'For the MITOX investigators: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial', Journal of the American Medical Association, 288, pp. 207 - 215
,2002, 'Insulin resistance and HIV-related lipoatrophy', Journal of the American Medical Association, 288, pp. 1716, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000178484700016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
,2002, 'Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: The OzCombo 2 Study', HIV Clinical Trials, 3, pp. 177 - 185
,2001, 'Hepatitis A epidemiology in Australia: national seroprevalence and notifications', Medical Journal of Australia, 174, pp. 338 - 341
,2000, 'Notifications of vaccine preventable diseases in Australia. Quarterly report (January-March 2000).', Communicable diseases intelligence, 24, pp. 239 - 241
,2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998.', Communicable diseases intelligence, 24, pp. 276 - 277
,2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998.', Communicable diseases intelligence, Suppl
,2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998', Communicable Diseases Intelligence Quarterly Report
,2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998.', Commun Dis Intell, Suppl, pp. v - 83, https://www.ncbi.nlm.nih.gov/pubmed/12049363
,1999, 'Australia's notifiable diseases status, 1998. Annual report of the National Notifiable Diseases Surveillance System.', Communicable diseases intelligence, 23, pp. 277 - 305
,1999, 'Hepatitis A in Australia in the 1990s: future directions in surveillance and control', Communicable Diseases Intelligence, 23, pp. 113 - 120
,1999, 'Measles-mumps-rubella immunisation, autism and inflammatory bowel disease: update', Communicable Diseases Intelligence Quarterly Report
,1998, 'Ross River virus infection in the north-west outskirts of the Sydney basin', Communicable Diseases Intelligence Quarterly Report, 22, pp. 101 - 102
,